Cargando…

Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients

BACKGROUND: Humoral immunity plays an important role against Pneumocystis jirovecii infection, yet clinical and environmental factors that impact bronchoalveolar antibody responses to P. jirovecii remain uncertain. METHODS: From October 2008—December 2011 we enrolled consecutive HIV-infected adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Blount, Robert J., Daly, Kieran R., Fong, Serena, Chang, Emily, Grieco, Katherine, Greene, Meredith, Stone, Stephen, Balmes, John, Miller, Robert F., Walzer, Peter D., Huang, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503245/
https://www.ncbi.nlm.nih.gov/pubmed/28692651
http://dx.doi.org/10.1371/journal.pone.0180212
_version_ 1783249062194053120
author Blount, Robert J.
Daly, Kieran R.
Fong, Serena
Chang, Emily
Grieco, Katherine
Greene, Meredith
Stone, Stephen
Balmes, John
Miller, Robert F.
Walzer, Peter D.
Huang, Laurence
author_facet Blount, Robert J.
Daly, Kieran R.
Fong, Serena
Chang, Emily
Grieco, Katherine
Greene, Meredith
Stone, Stephen
Balmes, John
Miller, Robert F.
Walzer, Peter D.
Huang, Laurence
author_sort Blount, Robert J.
collection PubMed
description BACKGROUND: Humoral immunity plays an important role against Pneumocystis jirovecii infection, yet clinical and environmental factors that impact bronchoalveolar antibody responses to P. jirovecii remain uncertain. METHODS: From October 2008—December 2011 we enrolled consecutive HIV-infected adults admitted to San Francisco General Hospital (SFGH) who underwent bronchoscopy for suspected Pneumocystis pneumonia (PCP). We used local air quality monitoring data to assign ozone, nitrogen dioxide, and fine particulate matter exposures within 14 days prior to hospital admission. We quantified serum and bronchoalveolar lavage fluid (BALF) antibody responses to P. jirovecii major surface glycoprotein (Msg) recombinant constructs using ELISA. We then fit linear regression models to determine whether PCP and ambient air pollutants were associated with bronchoalveolar antibody responses to Msg. RESULTS: Of 81 HIV-infected patients enrolled, 47 (58%) were diagnosed with current PCP and 9 (11%) had a prior history of PCP. The median CD4+ count was 51 cells/μl (IQR 15–129) and 44% were current smokers. Serum antibody responses to Msg were statistically significantly predictive of BALF antibody responses, with the exception of IgG responses to MsgC8 and MsgC9. Prior PCP was associated with increased BALF IgA responses to Msg and current PCP was associated with decreased IgA responses. For instance, among patients without current PCP, those with prior PCP had a median 73.2 U (IQR 19.2–169) IgA response to MsgC1 compared to a 5.00 U (3.52–12.6) response among those without prior PCP. Additionally, current PCP predicted a 22.5 U (95%CI -39.2, -5.82) lower IgA response to MsgC1. Ambient ozone within the two weeks prior to hospital admission was associated with decreased BALF IgA responses to Msg while nitrogen dioxide was associated with increased IgA responses. CONCLUSIONS: PCP and ambient air pollutants were associated with BALF IgA responses to P. jirovecii in HIV-infected patients evaluated for suspected PCP.
format Online
Article
Text
id pubmed-5503245
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55032452017-07-25 Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients Blount, Robert J. Daly, Kieran R. Fong, Serena Chang, Emily Grieco, Katherine Greene, Meredith Stone, Stephen Balmes, John Miller, Robert F. Walzer, Peter D. Huang, Laurence PLoS One Research Article BACKGROUND: Humoral immunity plays an important role against Pneumocystis jirovecii infection, yet clinical and environmental factors that impact bronchoalveolar antibody responses to P. jirovecii remain uncertain. METHODS: From October 2008—December 2011 we enrolled consecutive HIV-infected adults admitted to San Francisco General Hospital (SFGH) who underwent bronchoscopy for suspected Pneumocystis pneumonia (PCP). We used local air quality monitoring data to assign ozone, nitrogen dioxide, and fine particulate matter exposures within 14 days prior to hospital admission. We quantified serum and bronchoalveolar lavage fluid (BALF) antibody responses to P. jirovecii major surface glycoprotein (Msg) recombinant constructs using ELISA. We then fit linear regression models to determine whether PCP and ambient air pollutants were associated with bronchoalveolar antibody responses to Msg. RESULTS: Of 81 HIV-infected patients enrolled, 47 (58%) were diagnosed with current PCP and 9 (11%) had a prior history of PCP. The median CD4+ count was 51 cells/μl (IQR 15–129) and 44% were current smokers. Serum antibody responses to Msg were statistically significantly predictive of BALF antibody responses, with the exception of IgG responses to MsgC8 and MsgC9. Prior PCP was associated with increased BALF IgA responses to Msg and current PCP was associated with decreased IgA responses. For instance, among patients without current PCP, those with prior PCP had a median 73.2 U (IQR 19.2–169) IgA response to MsgC1 compared to a 5.00 U (3.52–12.6) response among those without prior PCP. Additionally, current PCP predicted a 22.5 U (95%CI -39.2, -5.82) lower IgA response to MsgC1. Ambient ozone within the two weeks prior to hospital admission was associated with decreased BALF IgA responses to Msg while nitrogen dioxide was associated with increased IgA responses. CONCLUSIONS: PCP and ambient air pollutants were associated with BALF IgA responses to P. jirovecii in HIV-infected patients evaluated for suspected PCP. Public Library of Science 2017-07-10 /pmc/articles/PMC5503245/ /pubmed/28692651 http://dx.doi.org/10.1371/journal.pone.0180212 Text en © 2017 Blount et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Blount, Robert J.
Daly, Kieran R.
Fong, Serena
Chang, Emily
Grieco, Katherine
Greene, Meredith
Stone, Stephen
Balmes, John
Miller, Robert F.
Walzer, Peter D.
Huang, Laurence
Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title_full Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title_fullStr Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title_full_unstemmed Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title_short Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients
title_sort effects of clinical and environmental factors on bronchoalveolar antibody responses to pneumocystis jirovecii: a prospective cohort study of hiv+ patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503245/
https://www.ncbi.nlm.nih.gov/pubmed/28692651
http://dx.doi.org/10.1371/journal.pone.0180212
work_keys_str_mv AT blountrobertj effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT dalykieranr effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT fongserena effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT changemily effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT griecokatherine effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT greenemeredith effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT stonestephen effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT balmesjohn effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT millerrobertf effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT walzerpeterd effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients
AT huanglaurence effectsofclinicalandenvironmentalfactorsonbronchoalveolarantibodyresponsestopneumocystisjiroveciiaprospectivecohortstudyofhivpatients